Addiction and endogenous cannabinoid system: The role of cannabinoid receptor CB1 in the mesotelencephalic dopaminergic neurones physiology;Adiccion y sistema cannabinoide endogeno: Papel del receptor para cannabinoides CB1 en la fisiologia de las neuronas dopaminergicas mesotelencefalicas

Adicciones

Volumn 12, Issue SUPPL. 2, 2000, Pages 83-95

  Rodriguez De Fonseca, F ^a   Navarro, M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Addiction; Cannabinoid receptors; Cannabinoid system; Cannabis; Dopaminergic system

Indexed keywords

ALCOHOL; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 1; CANNABINOID RECEPTOR 2; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

CANNABIS ADDICTION; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; HYPERACTIVITY; MESENCEPHALON; NONHUMAN; REVIEW; REWARD; SIGNAL PROCESSING; STRIATE CORTEX;

EID: 0033635621     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.673     Document Type: Review

References (71)

1. The cannabinoid agonist WIN 55,212-2 and CP 55,940 attenuate rotational behaviour induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway
2. Cannabis and Schizophrenia: A longitudinal study of Swedish conscripts
3. Reversal of dopamine D-2 receptor-mediated responses by an anandamide transport inhibitor
4. Functional role of high-affinity anandamide transport as revealed by selective inhibition
5. Influence of cannabinoids on electrically evoked dopamine release and cAMP generation in the rat striatum
6. Delta-9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis
7. Tetrahydrocannabinol for tremor in multiple sclerosis
8. Determination and characterization of a cannabinoid receptor in rat brain
9. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
10. Cannabinoid Pharmacology
11. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors
12. Mesolimbic dopaminergic decline after cannabinoid withdrawal
13. Lasting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal
14. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra
15. Isolation, structure and partial synthesis on an active constituent of hashish
16. 9-tetrahydrocannabinol
17. Cannabinoid transmission and reward-related events
18. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors
19. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum
20. Modulation of neurotransmission by cannabinoids in the basal ganglia
21. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor
22. Chronic treatment with (-)- delta-9-tetrahydrocannabinol results in sensitization to the psychomotor effects of amphetamine
23. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia
24. The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat
25. A longitudinal study of marijuana effects
26. Role of cyclic AMP dependent protein kinase in cannabinoid receptor modulation of potassium 'A-current' in cultured hippocampal neurons
27. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat
28. Cannabinoid receptor localization in brain
29. Pharmacology of cannabinoid receptors
30. Cannabis and neuroleptics agents in schizophrenia
31. 9-tetrahydrocannabinol: Possible mediation by glucocorticoid systems
32. Mesocorticolimbic dopaminergic network: Functional and regulatory roles
33. Elevated endogenous cannabinoids in schizophrenia
34. Cannabinoids inhibit N-Type calcium channels in neuroblastoma-glioma cells
35. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautoagraphy and in situ hybridization histochemistry
36. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study
37. Paradoxical action of the cannabinod WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices
38. Modulation of GABAergic transmission in the globus pallidus by the synthetic canabinoid WIN 55,212-2
39. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson'S disease
40. Characterization of the acute endocrine actions of HU-210, a potent synthetic cannabinoid in rats
41. Localization of Cannabinoid Receptor mRNA in rat brain
42. Structure of a brain cannabinoid receptor and functional expression of the cloned cDNA
43. Identification of an endogenous 2-monoglyceride present in canine gut that binds to cannabinoid receptor
44. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures
45. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats
46. Motor disturbances induced by an acute dose of delta-9-tetrahydrocannabinol: Possible involvement of nigrostriatal dopaminergic alterations
47. Acute administration of the CB1 receptor antagonist SR 141716A induces anxiety-like responses in the rat
48. The effect of delta-9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: An in vivo electrochemical and in vivo microdialysis study
49. Cannabis psychosis: A five year follow-up study
50. A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain
51. Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide
52. Pathophysiological basis of vulnerability to drug abuse: Role of an interaction between stress, glucocorticoids and dopaminergic neurons
53. SR 141716A a potent and selective antagonist of the brain cannabinoid receptor
54. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal
55. 9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas
56. 9-tetrahydrocannabinol treatment
57. Role of the endogenous cannabinoid system in the regulation of motor activity
58. Repeated stimulation of D-1 dopamine receptors enhances (-)-11-hydroxy-?8-tetrahydrocannabinol-dimethylheptyl-induced catalepsy in male rats
59. Cannabinoid receptor antagonist SR 141716 A decreases operant ethanol self-administration in rats exposed to ethanol-vapor chambers
60. Effects of THC on VIP-induced prolactin secretion in pituitary cultures: Evidence for the presence of functional cannabinoid receptors in pituitary cells
61. Involvement of GABA-B receptors in the motor inhibition produced by agonists of brain cannabinoid receptors
62. Effects of intranigral cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system
63. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat
64. Effects of intrapallidal cannabinoids on rotational behavior in rats. Interaction with the dopaminergic system
65. Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgS autoradiography in rat brain
66. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice
67. A second endogenous cannabinoid that modulates long-term potentiation
68. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons
69. Cannabinoid and heroin activation of mesolimbic dopaminetransmission by a common mu1 opioid receptor mechanism
70. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA
71. Immunohystochemical distribution of cannabinoid CB1 receptors in the rat central nervous system